Literature DB >> 25798260

Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios.

Melahat Yildirim1, Busra Demir Cendek2, Ayse Filiz Avsar3.   

Abstract

The aim of this study was to evaluate the association between preoperative neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) and the pathological diagnosis of adnexal masses. The predictive effect of inflammatory markers on epithelial ovarian cancer was also investigated. The present study included a total of 306 patients with adnexal masses who underwent surgical resection and the diagnosis was based on pathological investigation. The patients were divided into six groups based on their pathological findings and compared with respect to their NLR and PLR values. We used receiver-operating characteristic curves to calculate optimal cut-off values for NLR and PLR to predict ovarian cancer preoperatively. Patients with ovarian cancer exhibited significantly higher NLR and PLR values (P<0.05 and P<0.001, respectively). The multivariate analysis demonstrated that higher NLR and PLR values predicted ovarian cancer at the cut-off value of 3.35, sensitivity of 55% and specificity of 81% for NLR [95% confidence interval (CI): 0.544-0.752, P<0.05] and at the cut-off value of 572.9, sensitivity of 100% and specificity of 0.38% for PLR (95% CI: 0.192-0. 381, P=0.001). Therefore, preoperative NLR and PLR values may help identify ovarian cancer in patients with adnexal masses.

Entities:  

Keywords:  benign ovarian masses; neutrophil-to-lymphocyte ratio; ovarian cancers; platelet-to-lymphocyte ratio

Year:  2014        PMID: 25798260      PMCID: PMC4360876          DOI: 10.3892/mco.2014.481

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  23 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer.

Authors:  Gudrun Absenger; Joanna Szkandera; Michael Stotz; Ulrich Postlmayr; Martin Pichler; Anna Lena Ress; Renate Schaberl-Moser; Hans Loibner; Hellmut Samonigg; Armin Gerger
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

3.  Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.

Authors:  S K Allensworth; C L Langstraat; J R Martin; M A Lemens; M E McGree; A L Weaver; S C Dowdy; K C Podratz; J N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2013-06-05       Impact factor: 5.482

4.  Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.

Authors:  Viren Asher; Joanne Lee; Anni Innamaa; Anish Bali
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

5.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

6.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer.

Authors:  D C McMillan; K Canna; C S McArdle
Journal:  Br J Surg       Date:  2003-02       Impact factor: 6.939

7.  Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.

Authors:  Hanbyoul Cho; Hye Won Hur; Sang Wun Kim; Sung Hoon Kim; Jae Hoon Kim; Young Tae Kim; Kook Lee
Journal:  Cancer Immunol Immunother       Date:  2008-04-15       Impact factor: 6.968

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.

Authors:  Susan H Wei; Chuan-Mu Chen; Gordon Strathdee; Jaturon Harnsomburana; Chi-Ren Shyu; Farahnaz Rahmatpanah; Huidong Shi; Shu-Wing Ng; Pearlly S Yan; Kenneth P Nephew; Robert Brown; Tim Hui-Ming Huang
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

10.  Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer.

Authors:  Takafumi Watanabe; Masahiko Shibata; Hiroshi Nishiyama; Shu Soeda; Shigenori Furukawa; Kenji Gonda; Seiichi Takenoshita; Keiya Fujimori
Journal:  Oncol Lett       Date:  2013-12-06       Impact factor: 2.967

View more
  12 in total

Review 1.  The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Anastasia Prodromidou; Panagiotis Andreakos; Charalampos Kazakos; Dimitrios Eftimios Vlachos; Despina Perrea; Vasilios Pergialiotis
Journal:  Inflamm Res       Date:  2017-03-04       Impact factor: 4.575

2.  Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.

Authors:  M Polat; T Senol; E Ozkaya; G Ogurlu Pakay; M S Cikman; B Konukcu; M A Ozten; A Karateke
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

3.  Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer.

Authors:  Katarzyna Bednarska; Ewa Król; Ewa Głowacka; Hanna Romanowicz; Krzysztof Szyłło; Magdalena Klink; Zofia Sułowska; Marek Nowak
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

4.  Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer.

Authors:  Yun-Ji Kim; Inha Lee; Young Shin Chung; EunJi Nam; Sunghoon Kim; Sang-Wun Kim; Young Tae Kim; Jung-Yun Lee
Journal:  Obstet Gynecol Sci       Date:  2018-02-05

5.  Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses.

Authors:  Wan Kyu Eo; Ki Hyung Kim; Eun Joo Park; Heung Yeol Kim; Hong-Bae Kim; Suk Bong Koh; Jeong Namkung
Journal:  J Cancer       Date:  2018-03-08       Impact factor: 4.207

6.  Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses.

Authors:  Lian Li; Jing Tian; Liwen Zhang; Luyang Liu; Chao Sheng; Yubei Huang; Hong Zheng; Fengju Song; Kexin Chen
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

7.  Evaluation of Combined Cancer Markers With Lactate Dehydrogenase and Application of Machine Learning Algorithms for Differentiating Benign Disease From Malignant Ovarian Cancer.

Authors:  Seri Jeong; Dae-Soon Son; Minseob Cho; Nuri Lee; Wonkeun Song; Saeam Shin; Sung-Ho Park; Dong Jin Lee; Min-Jeong Park
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

8.  Preoperative Neutrophil-to-lymphocyte Ratio Predicts Long-term Survival in Patients Undergoing Total Laryngectomy With Advanced Laryngeal Squamous Cell Carcinoma: A Single-center Retrospective Study.

Authors:  Yan Fu; Weiwei Liu; Dian OuYang; Ankui Yang; Quan Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

9.  Does preoperative neutrophil to lymphocyte or platelet to lymphocyte ratios have a role in predicting borderline ovarian tumors?

Authors:  Ghanim Khatib; Cenk Soysal; Cihan Çetin; Ümran Küçükgöz Güleç; Ahmet Barış Güzel; Nadi Keskin; Mehmet Ali Vardar; Derya Gümürdülü
Journal:  J Ovarian Res       Date:  2016-11-08       Impact factor: 4.234

Review 10.  The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis.

Authors:  Joanna L Sylman; Annachiara Mitrugno; Michelle Atallah; Garth W Tormoen; Joseph J Shatzel; Samuel Tassi Yunga; Todd H Wagner; John T Leppert; Parag Mallick; Owen J T McCarty
Journal:  Front Oncol       Date:  2018-03-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.